Research & Development: Page 39
-
PharmaVoice Team/PharmaVoice
The Next Generation of Cancer Immunotherapy
Researchers and drug developers are gaining a better understanding of the immune system and how to better target cancer; as a result, immuno-oncology continues to be a key area of anticancer drug development. Researchers over the last few years have found that the immune system has the capability...
By Denise Myshko • Feb. 1, 2017 -
PharmaVoice Team/PharmaVoice
Update on Zika Research
First identified in Uganda in 1947, the Zika virus over the past two years has rapidly spread through Asia, the South Pacific, Hawaii, South America, Central America, and the Caribbean. In 2016, active local mosquito-borne transmission began to occur in North America, specifically in Florida and ...
By Denise Myshko • Feb. 1, 2017 -
Explore the Trendline➔
Stock via Getty Images
TrendlineOncology
As investments in cancer R&D stay high, waves of innovative new treatments are on the horizon.
By PharmaVoice staff -
PharmaVoice Team/PharmaVoice
Rare Disease Day Turns Spotlight on Research
On the last day in February, hundreds of patients’ groups from around the world will hold a host of activities to raise awareness about rare diseases. The international 10th annual Rare Disease Day, which is coordinated by the European Organization for Rare Diseases (EURORDIS), seeks to help the ...
By Kim Ribbink • Feb. 1, 2017 -
PharmaVoice Team/PharmaVoice
SHOWCASE FEATURE: Outsourcing: The Outsourcing Big Picture
Outsourcing is now firmly entrenched in the pharma industry. While pharmaceutical companies have been outsourcing back-office activities for many years now, they are increasingly turning to external partners for research and development activities that traditionally were retained in-house. Today,...
By PharmaVoice Team • Feb. 1, 2017 -
PharmaVoice Team/PharmaVoice
3-D Outsourcing: The Key to Improved Product Launches
Put yourself in this situation: You are the director of operations at a growing biotech company. It is either your first product launch or your previous product launches have been slow, inefficient and costly. It is up to you to improve commercialization by streamlining processes and using limite...
By Steve Devrieze • Feb. 1, 2017 -
PharmaVoice Team/PharmaVoice
Speak Out
Maximizing Patient Recruitment in Rare Disease Research Creating a pharmaceutical develop- ment program for the treatment of a rare disease is challenging. From re-cruiting and retaining patients and investi- gators, through to regulatory uncertainties and limited understanding of the natural his...
By Jeffrey Zucker • Feb. 1, 2017 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
Welcome to 2017 From funding to policy changes, 2017 according to analysts will be marked by uncertainty and opportunity. As the industy, as well as the country, prepares for the Trump Administration, EY U.S. Analyst Arda Ural, Ph.D., details the impact the new president’s policies will have on d...
By Taren Grom • Jan. 1, 2017 -
PharmaVoice Team/PharmaVoice
Innovator's Corner
A New Way to Treat Severe Asthma Dr. Bing Yao, Respiratory, Inflammation & Autoimmunity Head at MedImmune, talks about the company’s efforts to develop a next-generation asthma therapy. Severe, uncontrolled asthma is a debilitating and potentially fatal form of the disease. Uncontrolled asthm...
By Dr. Bing Yao • Jan. 1, 2017 -
PharmaVoice Team/PharmaVoice
HealthTech
AI and mHealth Tech: Instruments to Better Healthcare Computers can be trained to be more accurate than pathologists in assessing slides of lung cancer tissues, according to a study by researchers at the Stanford University School of Medicine. The researchers found that a machine-learning approac...
By PharmaVoice Team • Jan. 1, 2017 -
PharmaVoice Team/PharmaVoice
Last Word
Rising Pharma Opportunities in China Rick Pauls, President and CEO of DiaMedica, talks about how the Chinese market is poised for growth. PV: Why do you think the Chinese market has potential for the pharmaceutical industry? Pauls: The westernization of China is leading to increases in many disea...
By Rick Pauls • Jan. 1, 2017 -
PharmaVoice Team/PharmaVoice
Venture Capital Funding
According to the MoneyTree Report from PwC, the life-sciences industry continues to be the second most invested destination after software, in terms of dollars. Life-Sciences’ VC Investment The life-sciences’ record-high investment spree of 2015 came to an end in Q4 with the lowest quarter of in...
By PharmaVoice Team • Jan. 1, 2017 -
PharmaVoice Team/PharmaVoice
Organs On Chips
One day, precision medicine will take into account the genes, environment, and lifestyle of each person. Through the use of an emerging technology that melds engineering, biology, and IT, researchers are able to see what hasn’t been possible before: the inner workings of human biology and disease...
By Denise Myshko • Jan. 1, 2017 -
PharmaVoice Team/PharmaVoice
Disease State: HIV Update
Since the beginning of the HIV epidemic, almost 70 million people worldwide have been infected with the virus that causes AIDS. It is estimated that 36.7 million people are currently living with HIV globally. Tremendous gains have been made in treating these patients, helping them to live longer,...
By Denise Myshko • Jan. 1, 2017 -
PharmaVoice Team/PharmaVoice
Focus on Rare Diseases
Rare diseases have been a focus of drug development for decades, and since the 1980s, there have been financial, legal, and legislative incentives, such as the Orphan Drug Act, that are drawing companies of all sizes to enter the market. Rafal Kokolus, senior engagement manager, inVentiv Health C...
By PharmaVoice Team • Jan. 1, 2017 -
PharmaVoice Team/PharmaVoice
Pharma Trax
CROs are Leading Drive to Improve the Efficiency of Clinical Trials Trending now: Survey reveals significant improvements in inspection readiness among CROs. A global industry survey by Veeva of trial master file (TMF) owners shows growing use of electronic trial master file (eTMF) solutions a...
By PharmaVoice Team • Nov. 21, 2016 -
PharmaVoice Team/PharmaVoice
Tools of the Trade
Deloitte Launches ExaLink, a Multi-Services Platform for Commercial Operations Trending now: New platform helps pharma companies transcend legacy enterprise systems. Deloitte has released a hybrid cloud-based, multi-services platform, ExaLink, to help life-sciences companies transform their comm...
By PharmaVoice Team • Nov. 21, 2016 -
PharmaVoice Team/PharmaVoice
Trending 2017: Combination Products
Combination products are products that combine two or more different types of FDA-regulated products, including drugs, biologics, and medical devices. Regulators are working to make this process easier with the establishment of the Combination Product Council, identifying process improvements, an...
By PharmaVoice Team • Nov. 21, 2016 -
PharmaVoice Team/PharmaVoice
Trending 2017: Industrial Internet
The Industrial Internet, a term coined by GE, is the integration of complex physical machinery with networked sensors and software. The next state of the Industrial Internet will enable artificial intelligence to make meaningful use of device-collected data. This near future state is generating e...
By PharmaVoice Team • Nov. 21, 2016 -
PharmaVoice Team/PharmaVoice
Trending 2017: Smart Technology
The ability to capture health information in real time is changing the face of healthcare and clinical trials. Take for example Novartis and Qualcomm’s next-generation inhaler that enables patients to have access to their own data on the use of their inhaler in near real time. The small, disposab...
By PharmaVoice Team • Nov. 21, 2016 -
PharmaVoice Team/PharmaVoice
Trending 2017: Talent War
For most organizations the war for talent isn’t just with their competitors; it’s a battle being waged on a global basis that transcends industries. As global megatrends escalate, companies are reshaping their businesses and innovating to meet new market demands. The challenge is talent innovatio...
By PharmaVoice Team • Nov. 21, 2016 -
PharmaVoice Team/PharmaVoice
Data-driven Site Selection Accelerating Your Trials Through Predictive Site Modeling
Accelerated study start-up is the universally acknowledged holy grail of streamlining clinical trial operations. While advancements like central IRB review, adaptive trial designs, and the implementation of electronic systems have led to increased efficiencies across the clinical trial enterprise...
By Suzanne Caruso • Nov. 21, 2016 -
PharmaVoice Team/PharmaVoice
Speak Out
Changing the Drug Development Playbook –MODEL-INFORMED DRUG DEVELOPMENT HAS ARRIVED Imagine that you can reduce the number of patients required for a complex, hard-torecruit clinical trial by ten-fold. Imagine that you can use technology alone to add dosing information for special populations – s...
By PharmaVoice Team • Nov. 21, 2016 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
Clinical Data in Real Time The number of clinical trials using mobile apps more than doubled, rising from 135 in 2014 to 300 in 2015, according to the IMS Health Study Patient Options Expand as Mobile Healthcare Apps Address Wellness and Chronic Disease Treatment Needs. No doubt when 2016 numbers...
By Taren Grom • Oct. 1, 2016 -
PharmaVoice Team/PharmaVoice
Upfront
Industry at Large BMS Employees Cycle Coast to Coast to Raise Money for Cancer Research The first of six teams of Bristol-Myers Squibb oncology employees set out in September from Cannon Beach on the Oregon coast on the first leg of the 2016 Coast 2 Coast 4 Cancer Ride, a 21-day cycling ride that...
By PharmaVoice Team • Oct. 1, 2016 -
PharmaVoice Team/PharmaVoice
Innovator's Corner
A New Era for “Bubble Boy" Disease Sven Kili, M.D., head of gene therapy development at GlaxoSmithKline, talks about the company’s gene therapy to treat a very rare immune system disorder, which recently received EU approval. Children born with a specific immune disorder — severe combined immunod...
By Sven Kili • Oct. 1, 2016
Previous
